These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2782476)

  • 41. An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol.
    Zhang-Wong J; Beiser M; Zipursky RB; Bean G
    Psychiatry Res; 1998 Dec; 81(3):333-9. PubMed ID: 9925184
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
    Peuskens J
    Br J Psychiatry; 1995 Jun; 166(6):712-26; discussion 727-33. PubMed ID: 7545060
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
    Van Putten T; Marder SR; Mintz J; Poland RE
    Am J Psychiatry; 1992 Apr; 149(4):500-5. PubMed ID: 1554036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes.
    Krakowski M; Czobor P; Volavka J
    Psychiatry Res; 1997 Jun; 71(1):19-26. PubMed ID: 9247978
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
    Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
    J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response.
    Piscitelli SC; Frazier JA; McKenna K; Albus KE; Grothe DR; Gordon CT; Rapoport JL
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():94-7. PubMed ID: 7961584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia.
    Kane JM; Davis JM; Schooler N; Marder S; Casey D; Brauzer B; Mintz J; Conley R
    Am J Psychiatry; 2002 Apr; 159(4):554-60. PubMed ID: 11925292
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
    Miller DD; Perry PJ; Kelly MW; Coryell WH; Arndt SV
    J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
    Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
    J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study.
    McEvoy JP; Stiller RL; Farr R
    J Clin Psychopharmacol; 1986 Jun; 6(3):133-8. PubMed ID: 3711363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pilot study of a structured interview addressing sexual function in men with schizophrenia.
    Burke MA; McEvoy JP; Ritchie JC
    Biol Psychiatry; 1994 Jan; 35(1):32-5. PubMed ID: 8167201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration.
    Möller HJ; Kissling W; Lang C; Doerr P; Pirke KM; von Zerssen D
    Am J Psychiatry; 1982 Dec; 139(12):1571-5. PubMed ID: 7149056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An open trial of buspirone added to neuroleptics in schizophrenic patients.
    Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
    J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dosage of haloperidol for schizophrenia.
    Rifkin A; Doddi S; Karajgi B; Borenstein M; Wachspress M
    Arch Gen Psychiatry; 1991 Feb; 48(2):166-70. PubMed ID: 1989572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
    Wright P; Lindborg SR; Birkett M; Meehan K; Jones B; Alaka K; Ferchland-Howe I; Pickard A; Taylor CC; Roth J; Battaglia J; Bitter I; Chouinard G; Morris PL; Breier A
    Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol.
    Patris M; Agussol P; Alby JM; Brion S; Burnat G; Castelnau D; Deluermoz S; Dufour H; Ferreri M; Goudemand M
    Acta Psychiatr Scand Suppl; 1990; 358():78-82. PubMed ID: 1978497
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
    Peuskens J; Gillain B; De Graeve D; Van Vleymen B; Albert A
    Eur Psychiatry; 2009 Apr; 24(3):154-63. PubMed ID: 19118983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diurnal variations of extrapyramidal symptoms induced by haloperidol in schizophrenic subjects.
    Torner C; Herrera-Estrella M; Gutiérrez JA; Aguilar-Roblero R
    Int J Neuropsychopharmacol; 2003 Sep; 6(3):243-6. PubMed ID: 12974990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.